2
5 chemotherapy, the development of chemo-resistant disease is common and can bring profound changes in subclonal architecture and mutation profiles (6) (7) (8) .
Despite this complexity, there is a strong link between anti-tumor immunity and patient survival in HGSC, suggesting the immune system can contend with tumor heterogeneity in a substantial proportion of cases. In particular, the presence of CD8+ tumor-infiltrating lymphocytes (TIL) in primary tumors carries a >2-fold increased likelihood of survival (9).
Importantly, however, CD8+ TIL do not operate in isolation. We have shown that tumors containing CD8+ TIL are often additionally infiltrated by CD20+ B cells (10, 11) . CD20+ TIL exhibit an antigen-experienced, immunoglobulin G (IgG) positive memory phenotype (11).
Importantly, tumors containing both CD8+ and CD20+ TIL are associated with higher survival rates than those containing CD8+ TIL alone. Similar results have been reported in a variety of other cancers (12) (13) (14) , suggesting that effective tumor immunity involves cooperative interactions between T cells and B cells.
In our prior study (11), we found that CD8+ and CD20+ TIL often co-localized in lymphoid aggregates of various sizes and morphology. This is reminiscent of autoimmune conditions, where lymphoid aggregates develop in affected tissues. In rheumatoid arthritis, lymphoid aggregates have been classified into three grades ranging from small perivascular collections of B and T cells (grade 1) to large, highly organized structures resembling lymph nodes (grade 3) (15). These latter aggregates, referred to as tertiary lymphoid structures (TLS), are found not only in autoimmunity, but also in chronic infection, graft rejection, and cancer (16). Like conventional lymph nodes, TLS harbor prominent B cell follicles adjoined by discrete T cell zones containing CD4+ and CD8+ T cells, DC, and high endothelial venules (HEV) (16).
The B cell follicles of active TLS contain germinal centers (GC) with interdigitating networks of
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Author Manuscript Published OnlineFirst on January 13, 2016; DOI: 10.1158 /1078 -0432.CCR-15-2762 follicular dendritic cells (fDC). In the setting of cancer, TLS are receiving increased attention, as they have been associated with favorable prognosis in several solid tumors (17) (18) (19) .
To better understand the mechanisms by which T cells and B cells work together to mediate anti-tumor immunity, we investigated the co-localization patterns, phenotypes, and gene expression profiles of tumor-associated T-and B-lineage cells in HGSC. We found that the most robust, prognostically favorable CD8+ TIL responses are accompanied not only by CD20+ TIL but by dense stromal infiltrates of IgG+ plasma cells. We propose that optimal anti-tumor immunity may involve closely integrated cytolytic-and antibody-mediated effector mechanisms.
Materials and Methods:
Additional information is provided in Supplementary Materials.
Patient cohorts
The study protocol was approved by the Research Ethics Board of the BC Cancer Agency (BCCA) and University of British Columbia (Vancouver BC). HGSC tumor specimens were obtained from previously untreated patients from a prospective cohort (treated between 2007-present) or retrospective cohort (optimally de-bulked cases treated between 1984-2000; Table   S4 ) (10, 20) . Bioinformatic analyses utilized data from 570 untreated HGSC cases from The Cancer Genome Atlas (4). 7 software v12.1 (Aperio Technologies) with the Stereology Toolkit v4.2.0 (ADCIS). TIL were enumerated in ten random 20x fields, and cell counts were normalized to the area of tumor epithelium evaluated. PC density was measured using a four-point scale (21); for survival analyses, cases with PC scores >1 were deemed positive.
Flow cytometry
Disaggregated tumor cell suspensions were washed and labeled with fluorophoreconjugated monoclonal antibodies (Table S6) . Flow cytometry and sorting were performed using a BD Influx instrument (Mississauga ON).
IgG sequence analysis
RNA was extracted from FACS-purified memory B cells and plasma cells (1-5 x 10 3 each) and bulk tumor cells (2.5 x 10 6 ). PCR reactions were performed using primers designed to amplify all IGHG variable regions. Up to 192 clones per sample were subjected to Sanger sequencing.
NanoString gene expression analysis
Total RNA was prepared from FFPE whole tumor sections using the AllPrep DNA/RNA FFPE kit (Ambion, Life Technologies, Carlsbad CA). Total RNA (200 ng) was analyzed using the Pan Cancer Immune Profiling panel and nCounter platform (NanoString Technologies, Seattle WA). Data was normalized using nSolver software.
Bioinformatic analysis
The HGSC gene expression array dataset from The Cancer Genome Atlas (TCGA) was downloaded from bioconductor.org. Corresponding RNA-seq data, non-synonymous point
Author Manuscript Published OnlineFirst on January 13, 2016; DOI: 10.1158 /1078 -0432.CCR-15-2762 mutation counts, BRCA1, BRCA2, and TP53 mutation status, and BRCA1 promotor methylation calls were appended.
Statistical analysis
Statistical analyses were performed using R v3.1.1 and GraphPad Prism v6.0.
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Multicolor IHC reveals four types of lymphoid aggregate in HGSC
To visualize the different lymphoid aggregates present in HGSC, we developed a 6-color IHC panel that enabled simultaneous detection of CD8+ and CD4+ (CD3+CD8-) T cells, CD20+ B cells, CD21+ follicular DC (fDC), CD208+ activated conventional DC (DC), and PNAd+ HEV-like vessels. The panel was applied to whole sections from 30 randomly selected HGSC tumors. To control for anatomical location, we stained an equal number of specimens from ovary or omentum; for 7 cases, we stained matched ovary and omentum samples to allow direct comparison between these sites.
We observed a variety of lymphoid aggregates, which we classified into four types based on size, cellular composition, and degree of organization. Type 1 aggregates were small (approximately 20 to 50 cells), compact, and composed of CD4+ and CD8+ T cells, B cells, and occasional DC (Fig. 1A) , thereby resembling grade 1 aggregates in RA (15). Type 2 aggregates were larger (100 to >1000 cells) and composed of CD4+ and CD8+ T cells and CD20+ B cells (Fig. 1B) . These aggregates were diffuse and lacked discrete zones or follicles. Type 3 aggregates represented fully developed TLS, similar to grade 3 aggregates in RA (15). TLS had prominent B cell follicles with germinal center (GC)-like structures characterized by interdigitating networks of CD21+ fDC. In addition, they contained discrete T cell zones with CD4+ and CD8+ T cells, DC, and PNAd+ HEV-like vessels (Fig. 1C) . Finally, Type 4 aggregates were composed of approximately 100-300 CD20+ B cells and fDC organized into follicles with few CD4+ and CD8+ T cells (Fig. 1D) . As these structures did not contain clear T cell zones and were primarily (6/7) found in omental samples, we speculated many or all were normal milky spots (22).
Research. January 13, 2016; DOI: 10.1158 /1078 -0432.CCR-15-2762 The four types of aggregate were strongly associated with one another. Type 1 and 2 aggregates were found in the same 17/30 tumors. TLS were found in 7/30 tumors, all of which contained Type 1 and 2 aggregates. Type 4 aggregates were observed in 7/30 tumors, of which 7/7 contained Type 1 and 2 aggregates and 5/7 contained TLS. There was a trend toward a higher prevalence of Type 1-3 aggregates in omental versus ovarian samples; however, this did not reach statistical signifiance. Given their high degree of coincidence, Type 1-3 aggregates could represent a developmental continuum of structures, as has been suggested for similar aggregates in rheumatoid arthritis (15). Alternatively, they could reflect distinct immunological processes underway in the tumor microenvironment.
All four types of aggregate were strongly associated with TIL. Tumors containing Type 1 or 2 aggregates were positive for CD4+ and CD8+ TIL in 17/17 cases and CD20+ TIL in 14/17 cases. Likewise, all tumors containing TLS (7/7) contained CD4+, CD8+, and CD20+ TIL (Fig.   1E) . We compared the density of TIL in TLS-proximal (<500 µm from the TLS center) versus TLS-distal (>500 µm) tumor regions. CD20+ TIL showed a >10-fold greater density in TLSproximal epithelium (28.5 vs. 2.5 cells/20x field; P= 0.013, Mann-Whitney test; Fig. 1F ). CD4+ and CD8+ TIL showed a similar trend (72 vs. 24 and 227 vs. 59 cells/20x field, respectively), although this did not reach statistical significance (Fig. 1F) . TIL densities were similar between omental and ovarian sites (all P > 0.4, Mann-Whitney test).
TLS are associated with dense plasma cell infiltrates in tumor stroma
To investigate whether the GC-like structures observed in TLS were sites of B cell differentiation, sections containing TLS were subjected to three-color IHC with antibodies to BCL-6, CD3 and CD20. We detected nuclear expression of BCL-6 in both CD20+ and CD3+
Research. Fig.   2A) . Moreover, virtually all TLS contained AID+ CD20+ B cells, which are indicative of ongoing immunoglobulin class switching and somatic hypermutation (Fig. 2B) . BCL-6+ and AID+ B cells were also observed in Type 4 aggregates but not Type 1 or 2 aggregates. Thus, TLS exhibited the hallmarks of ongoing GC reactions.
Tumors were stained with antibodies to CD38, CD138 and CD79a to distinguish PCs (which are CD20-but co-express CD38, CD138, and cytosolic CD79a) from naive and memory B cells (which are CD38-CD138-but express membranous CD79a) and CD138+ tumor or stromal cells. PCs were found in 21/30 of tumors and generally formed dense stromal infiltrates, constituting 50-90% of stromal cells (Figs. 2C, D) . PCs were typically concentrated near the periphery of TLS (Fig. 2E) . In several cases, CD138+ cells were observed in GCs (Fig. 2F ).
There was a strong association between TLS and the density of stromal PCs (mean PC score in the presence of TLS = 2.6 vs. 1.0 in the absence of TLS, P = 0.0004, Mann-Whitney test; Fig.   2G ), although 2/30 tumors contained abundant PCs (PC score of 3) in the absence of TLS (Fig.   2G) . Thus, TLS-associated GCs could serve as sites of PC differentiation. The density of PCs was also positively associated with the intraepithelial density of CD4+, CD8+, and CD20+ TIL (all Spearman's r >0.6, P < 0.001; Fig. 2F ).
A coordinated antitumor response including PCs is associated with survival in HGSC
To assess the prognostic significance of tumor-associated PCs, we analyzed a retrospective HGSC tissue microarray which has been previously evaluated for numerous TIL subsets (10, 11, 23) . Consistent with our initial IHC analysis, PCs were found in 36% (62/172) of cases and showed a predominantly stromal location. When PCs were considered in relation to
Research. (Fig. 3A) . These subgroups were associated with stepwise increases in the densities of CD8+, CD4+ and CD20+ TIL (all ANOVA P<0.0001). The density of CD25+FoxP3+ TIL (23) followed a similar pattern (ANOVA P=0.0007). TIL patterns showed no association with patient age or stage of disease (ANOVA P=0.777, respectively) . Thus, PCs were associated with increasingly dense infiltrates of both effector and regulatory T cells.
The six subgroups carried distinct prognostic significance (Fig. 3B) . The survival rate associated with CD8+ TIL alone was similar to tumors lacking TIL altogether. Of tumors containing CD8+ TIL, those that additionally contained CD4+ TIL, CD20+ TIL or PCs were associated with minor, statistically insignificant increases in survival. However, tumors containing CD8+, CD4+ and CD20+ TIL together with PCs were associated with markedly increased survival, with approximately 65% of patients alive at 10 years. Thus, the prognostic benefit of CD8+ TIL was restricted to tumors that additionally harbor PCs and these other TIL subsets.
Tumor-associated PCs are IgG+CXCR3+ and clonally expanded
The phenotype of PCs was further defined by flow cytometry of disaggregated viable tumor samples corresponding to 12/30 cases used in our multicolor IHC analysis above (Figs. 1,   2 CD19+ cells were further assessed for expression of B cell differentiation markers. As expected, naive B cells were CD20+CD27-CD95-CD138-, and memory B cells were CD20+CD27+CD95+CD138- (Fig. 4C) . Also as expected, PCs were CD20-CD27+CD95+ and showed low but consistent expression of CD138 (Fig. 4C) . The chemokine receptors CXCR5 and CXCR3 recruit B-lineage cells into follicles and sites of inflammation, respectively. As expected, naive B cells expressed CXCR5 but not CXCR3, whereas the memory B cell population was a mixture of CXCR5+ and CXCR3+ cells (Fig. 4C) . In contrast, PCs universally expressed CXCR3 but not CXCR5. Thus, PCs appeared to be at an early stage of differentiation and had an inflammatory chemokine receptor profile.
To assess clonality, we FACS-purified PCs from 3 tumors and sequenced the Ig heavychain variable regions. Bulk tumor samples and FACS-purified memory B cells were analyzed for comparison. In 3/3 tumors, PC-derived sequences were restricted to 10-28 distinct VDJ families (Fig. 4D, Table S1 ), suggesting a high degree of clonal expansion. There was also widespread evidence of somatic hypermutation within VDJ families, with most sequences showing at least 5% divergence from germline. Although CDR3 sequences from PCs and memory B cells showed some overlap, PC-derived sequences were most similar to those from bulk tumor in terms of both diversity and prevalence (Fig. 4D) . Thus, PCs were clonally expanded and represented the predominant source of IgG mRNA in tumors. (Table S2 ). TNFRSF17/BCMA is known to be expressed when B cells differentiate into antibody-secreting cells (24), and it is essential for the survival of long-lived PCs but not memory B cells (25). Moreover, TNFRSF17 has been described as a signature gene for human PCs (26).
Given our observation that PCs contribute the majority of IgG mRNA in HGSC tumors ( Fig. 3D) , we reasoned that TNFRSF17 and IgG gene expression levels should be correlated.
Indeed, analysis of microarray data from 570 untreated HGSC tumor specimens in the TCGA dataset (27) revealed a strong correlation between the expression of TNFRSF17 and the pattern was seen using RNA-seq data from a subset of these tumors (Fig. 5C ). As expected, tumors that expressed both TNFRSF17 and IGJ also expressed high levels of IGHV segments (Fig. 5D) . The majority of such cases expressed 5-15 IGVH segments (Fig. 5D) , consistent with the oligoclonal nature of IgG transcripts previously observed by Sanger sequencing of IGHV regions (Fig. 4D) . Finally, in accord with our flow cytometry data (Fig. 4B) , IgG-derived transcripts were far more abundant than other immunoglobulin subtypes. Specifically, IGG1, IGG2, and IGG3 were predominant, with low expression of IGG4, IGA1, and IGM in some cases (Fig. S1) . Thus, TNFRSF17 and IGJ comprised a two-gene signature that distinguished TCGA cases with (a) both PCs and CD20+ TIL (TNFRSF17 
Association of the PC signature with immune-related genes, patient survival, and CT antigens
The TNFRSF17/IGJ gene signature was used to explore associations between PCs and other immune-related gene products in the TCGA gene expression microarray dataset. Consistent with our IHC data (Fig. 2E) , tumors with a PC signature (i.e., TNFRSF17 high and IGJ high ) showed elevated expression of CXCL13 (which contributes to the establishment and organization of TLS) and IL21 (which is produced primarily by Tfh cells) (Fig. 6A) . Although a marker of TLS, CXCL13 is unlikely to serve as a chemoattractant for PCs, as PCs express the inflammation- Author Manuscript Published OnlineFirst on January 13, 2016; DOI: 10.1158/1078-0432.CCR-15-2762 associated chemokine receptor CXCR3 rather than CXCR5 (Fig. 4C)(28) . Indeed, the three CXCR3 ligands (CXCL9, CXCL10 and CXCL11) were highly expressed in tumors with PC or B cell signatures (Fig. 6B) , providing a plausible mechanism for attraction of PCs to the tumor microenvironment. Tumors with a PC signature also showed high expression of TNFSF13B (BAFF, a ligand for BCMA) (Fig. 6C) . In contrast, IL6 levels were only modestly elevated, and TNFSF13 (APRIL) and CXCL12 levels were similar to the PC-negative subgroups (Fig. 6C) .
Thus, the BAFF/BCMA axis might provide the primary growth and survival signal for PCs in the HGSC microenvironment.
We also evaluated the relationship between PCs, cytolytic gene signatures, and prognosis. Consistent with our IHC data ( Fig. 2H) we observed a stepwise increase in the expression of CD8A (a marker of CD8+ TIL) in cases with B cell and PC signatures (Fig. 6D) , whereas expression of the Treg-associated transcription factor FOXP3 was uniform across subgroups (Fig. 6E) . Cases with the PC gene signature also showed elevated expression of IFNG, GZMB, and PRF1 (Fig. 6F) . The PC gene signature was strongly associated with overall survival (no B cells vs. PC, log-rank P=0.0086; B cells vs. PC P=0.0241), whereas IGJ alone carried no prognostic benefit (Fig. 6G) . Thus, consistent with our IHC data (Fig. 3B) , PCs were associated with cytotoxic immune responses and patient survival.
To gain insight into potential target antigens of PCs, we evaluated the relationship between the PC gene signature and various classes of tumor antigen. Non-synonymous point mutations can give rise to "neo-epitopes" that are recognized by CD8+ and CD4+ TIL (29). (Table S3 ) but found no association with the PC or B cell gene signatures (Fig. S2C) .
Finally, we assessed the expression of 104 cancer-testis (CT) antigens. Tumors with a PC signature expressed two-fold more CT antigens on average than tumors with a B cell signature or no B cell signature (cut-off: z=3, ANOVA P=0.0003; Fig. 6J ). Similar results were obtained using different thresholds for gene expression (z=2, P=0.0093 and z=4, P<0.0001). Semisupervised hierarchical clustering revealed a subset of CT antigens that were over-represented in cases with a PC gene signature (Fig. S3) , including known targets of autoantibody responses such as NY-ESO-1, MAGEA1 and CTAG2 ( Fig. S3; Table S4 ). Thus, from this broad bioinformatic analysis, CT antigens emerged as a potential class of target antigen underlying PC responses in HGSC.
Discussion:
While investigating lymphoid aggregates in HGSC, we discovered a novel, prognostically significant association between TIL, TLS, and PCs. PCs were strongly associated with mature TLS and formed dense aggregates in tumor stroma. PCs had an early differentiated phenotype, expressed surface IgG, and showed evidence of clonal expansion and somatic hypermutation. PC infiltrates were strongly associated with CD8+ TIL and other hallmarks of 
mediated tumor immunity and consequently the effectiveness of chemotherapy (36). Notably, this PC subset expressed IgA, IL-10 and PD-L1 and differentiated in response to TGF-beta. In contrast, we found that PCs in HGSC universally expressed IgG (Figs. 4B, S1 ), suggesting they undergo class switching in a pro-immune milieu dominated by cytokines such as IFN-γ rather than TGF-β. Moreover, HGSC-associated PCs expressed CXCR3 (Fig. 4C) , which is induced in B-lineage cells by an IFN-γ/T-bet dependent pathway and enables their recruitment to inflammatory sites (37). CXCR3+ PCs have also been described in autoimmunity, where they serve to exacerbate rather than suppress immune responses (38,39). Thus, the immunosuppressive PCs described in prostate cancer (36) may be unique to that disease, as the PCs found in HGSC and other malignancies have properties and associations consistent with a positive role in anti-tumor immunity.
Given the strong prognostic significance of CD8+ TIL, it is widely assumed that they are the primary mediators of anti-tumor immunity. However, CD8+ TIL are often functionally impaired in the tumor microenvironment (40), raising the possibility that alternative immune mechanisms are equally if not more important. As the normal physiological role of PCs is to serve as "antibody factories", they could mediate anti-tumor effects by producing antibodies against tumor-associated antigens. Such effects might be augmented by the dense localization of PCs in tumor stroma, which would enable high concentrations of antibody to accumulate locally.
Theoretically, PC-derived antibodies could mediate direct antitumor effects by binding to and disrupting the function of their cognate antigens, activating the complement pathway, and/or triggering antibody-dependent cellular cytotoxicity (ADCC) (41). In this regard, the predominant antibody subtypes in HGSC included IgG1 and IgG3 (Fig. S1) , which can activate both Defining the anti-tumor mechanisms used by PCs will require identification of their cognate antigens. Our TCGA analyses suggest that PC-derived antibodies preferentially recognize CT antigens over differentiation/overexpressed antigens or mutant gene products (Figs. 7, S2) . Of the 31 CT antigens that were associated with PC signature positive tumors (Table S4) 
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